foxo4-dri human study Frontiers FOXO4-DRI (Proxofim) 10mg*10 vials -

Statistical analysis of the quantified data was performed by analysis of variance (ANOVA)

Here is what patients commonly experience after consistent DSIP therapy

Common (Generally Mild) Nausea Vomiting Headache Mild sedation GI discomfort related to PN Metabolic Effects Elevated homocysteine (risk factor for thrombosis) Metabolic acidosis Hyperammonemia (especially in hepatic dysfunction) Elevated BUN/creatinine Hyperglycemia (from PN carbohydrates) Rare / Serious Hepatic dysfunction Allergic reactions to PN components Central line complications (infection, thrombosis) Refeeding syndrome (hypophosphatemia, hypokalemia, hypomagnesemia) Neurologic symptoms if severe ammonia elevation occurs Pregnancy & Breastfeeding Pregnancy Methionine is naturally required in pregnancy, and PN is considered safe and appropriate when medically indicated

Peptides for muscle growth and recovery take 2 to 6 weeks to show noticeable improvements in recovery, soreness, sleep, or workout performance

Only data from the second wave are described in this current study